Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous cell carcinoma

Published online: 12 February 2025 - ESMO Open

Obermannová RL & Leong T, on behalf of the ESMO Guidelines Committee

  • This update provides recommendations for perioperative treatment of locally advanced oesophageal and OGJ adenocarcinoma.
  • Recent phase III data have demonstrated that perioperative ChT should be the preferred approach for most patients.
  • Updated recommendations are also provided for the use of immune checkpoint inhibitors in advanced squamous cell carcinoma.
  • Algorithms for the management of locoregional oesophageal cancer and advanced squamous cell carcinoma are provided.
  • Recommendations are based on available scientific data and the authors’ collective expert opinion.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.